SPECIAL SECTION ON PREDICTION OF HUMAN PHARMACOKINETIC PARAMETERS FROM IN VITRO SYSTEMS

Prediction of Human Pharmacokinetics in 2013 and Beyond. J. Brian Houston ................................. 1973

A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. Li Di, Bo Feng, Theunis C. Goosen, Yurong Lai, Stefanus J. Steyn, Manthena V. Varma, and R. Scott Obach .................. 1975

Impact of Physiologically Based Pharmacokinetic Modeling and Simulation in Drug Development. Carole E. Shardlow, Grant T. Generaux, Aarti H. Patel, Guoying Tai, Thuy Tran, and Jackie C. Bloomer. ................. 1994

CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. Cong Xu, Sara K. Quinney, Yingying Guo, Stephen D. Hall, Lang Li, and Zeruesenay Desta .......... 2004

In Vitro P-glycoprotein Efflux Ratio Can Predict the In Vivo Brain Penetration Regardless of Biopharmaceutics Drug Disposition Classification System Class. Ryota Kikuchi, Sonia M. de Morais, and J. Cory Kalvass .................. 2012


Meeting the Challenge of Predicting Hepatic Clearance of Compounds Slowly Metabolized by Cytochrome P450 Using a Novel Hepatocyte Model, HepatoPac. Tom S. Chan, Hongbin Yu, Amanda Moore, Salman R. Khetani, and Donald Tweedie .......................... 2024


SHORT COMMUNICATION


ARTICLES

### Contents (cont’d.)

- Activity, Inhibition, and Induction of Cytochrome P450 2J2 in Adult Human Primary Cardiomyocytes. Eric A. Evangelista, Rüdiger Kaspera, Nahush A. Mokadam, J. P. Jones, III, and Rheem A. Totah .................................................. 2087

- Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multidrug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance. Hong Shen, Zheng Yang, Weiping Zhao, Yueping Zhang, and A. David Rodrigues ............................... 2095


- Metabolism and Excretion of 6-Chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an HSP90 Inhibitor, in Rats and Dogs and Assessment of Its Metabolic Profile in Plasma of Humans. Lin Xu, Caroline Woodward, Jing Dai, and Chandra Prakash ........................................... 2133

- In Vitro Metabolism of the Glucagon-Like Peptide-1 (GLP-1)–Derived Metabolites GLP-1(9-36)amide and GLP-1(28-36)amide in Mouse and Human Hepatocytes. Raman Sharma, Thomas S. McDonald, Heather Eng, Chris Limberakis, Benjamin D. Stevens, Sheena Patel, and Amit S. Kalpakkar ......... 2148


- Supplemental material is available online at http://dmd.aspetjournals.org.

---

About the cover: Simulation of the fold difference in prediction magnitude that would occur using the additive model instead of the inhibitor-inhibitor interaction model as a function of in vivo inhibitor potency. See article by Lutz et al. on page 2056 of this issue.